Literature DB >> 3570157

The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass.

J B Gross, J Reichen, T B Zeltner, A Zimmermann.   

Abstract

The aim of this study was to determine the prognostic significance of functional changes in the liver during progression of cirrhosis. Liver function was quantitated weekly by the aminopyrine breath test (measuring microsomal function) and the galactose breath test (measuring cytosolic function) in rats made cirrhotic by bile duct ligation (n = 14) and in sham-surgery controls (n = 9). Nine rats died spontaneously of cirrhosis. Both the aminopyrine breath test and galactose breath test were sensitive (89%) predictors of death within 1 week, but the galactose breath test was more specific (83%). Morphometric measurements of livers from surviving cirrhotic animals and controls (n = 5 each) showed that mean hepatocyte mass was maintained in the cirrhotic livers [cirrhosis (17.0 +/- 2.0) vs. controls (13.9 +/- 0.9 gm)]. The galactose breath test was also maintained, whereas the aminopyrine breath test was significantly decreased in the surviving cirrhotics. The galactose breath test, but not the aminopyrine breath test, correlated with hepatocyte mass (r = 0.67). The aminopyrine breath test correlated with microsomal aminopyrine N-demethylase activity (r = 0.78). Serial use of quantitative liver tests allows prediction of time of death from cirrhosis in this model.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570157     DOI: 10.1002/hep.1840070308

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate.

Authors:  B J Stähelin; U Marti; M Solioz; H Zimmermann; J Reichen
Journal:  Mol Pathol       Date:  1998-08

3.  Liver metabolic zonation and hepatic microcirculation in carbon tetrachloride-induced experimental cirrhosis.

Authors:  E Gaudio; P Onori; A Franchitto; R Sferra; O Riggio
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

4.  Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis.

Authors:  J Reichen; B Egger; N Ohara; T B Zeltner; T Zysset; A Zimmermann
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats.

Authors:  Halil Eken; Hayrettin Ozturk; Hulya Ozturk; Huseyin Buyukbayram
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

6.  Liver cirrhosis induces renal and liver phospholipase A2 activity in rats.

Authors:  B S Vishwanath; F J Frey; G Escher; J Reichen; B M Frey
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  Abnormal lipid composition of microsomes from cirrhotic rat liver--does it contribute to decreased microsomal function?

Authors:  J Reichen; J T Buters; Z Sojcic; F J Roos
Journal:  Experientia       Date:  1992-05-15

8.  Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score.

Authors:  C Merkel; A Gatta; M Zoli; M Bolognesi; P Angeli; T Iervese; G Marchesini; A Ruol
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

9.  Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats.

Authors:  S Dueland; J Reichen; G T Everson; R A Davis
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

10.  Generation of biliary lesions after transfer of human lymphocytes into severe combined immunodeficient (SCID) mice.

Authors:  S M Krams; K Dorshkind; M E Gershwin
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.